Literature DB >> 9422768

Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src.

L M Ellis1, C A Staley, W Liu, R Y Fleming, N U Parikh, C D Bucana, G E Gallick.   

Abstract

Vascular endothelial growth factor (VEGF) is implicated in the angiogenesis of human colon cancer. Recent evidence suggests that factors that regulate VEGF expression may partially depend on c-src-mediated signal transduction pathways. The tyrosine kinase activity of Src is activated in most colon tumors and cell lines. We established stable subclones of the human colon adenocarcinoma cell line HT29 in which Src expression and activity are decreased specifically as a result of a transfected antisense expression vector. This study determined whether VEGF expression is decreased in these cell lines and whether the smaller size and reduced growth rate of antisense vector-transfected cell lines in vivo might result, in part, from reduced vascularization of tumors. Northern blot analysis of these cell lines revealed that VEGF mRNA expression was decreased in proportion to the decrease in Src kinase activity. Under hypoxic conditions, cells with decreased Src activity had a <2-fold increase in VEGF expression, whereas parental cells had a >50-fold increase. VEGF protein in the supernatants of cells was also reduced in antisense transfectants compared with that from parental cells. In nude mice, subcutaneous tumors from antisense transfectants showed a significant reduction in vascularity. These results suggest that Src activity regulates the expression of VEGF in colon tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9422768     DOI: 10.1074/jbc.273.2.1052

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

Authors:  Rui Zheng; Seiji Yano; Yuka Matsumori; Emiko Nakataki; Hiroaki Muguruma; Masanori Yoshizumi; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

3.  Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Authors:  John H Strickler; Shannon McCall; Andrew B Nixon; John C Brady; Herbert Pang; Christel Rushing; Allen Cohn; Alexander Starodub; Christy Arrowood; Sherri Haley; Kellen L Meadows; Michael A Morse; Hope E Uronis; Gerard C Blobe; S David Hsu; S Yousuf Zafar; Herbert I Hurwitz
Journal:  Invest New Drugs       Date:  2013-11-01       Impact factor: 3.850

Review 4.  Molecular mechanisms of tumor angiogenesis and tumor progression.

Authors:  U Cavallaro; G Christofori
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

5.  Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Authors:  Eric B Haura; Tawee Tanvetyanon; Alberto Chiappori; Charles Williams; George Simon; Scott Antonia; Jhanelle Gray; Sharon Litschauer; Leticia Tetteh; Anthony Neuger; Lanxi Song; Bhupendra Rawal; Michael J Schell; Gerold Bepler
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation.

Authors:  Rotem Karni; Yael Gus; Yuval Dor; Oded Meyuhas; Alexander Levitzki
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

Review 7.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

8.  An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization.

Authors:  Bing Xie; Jikui Shen; Aling Dong; Mara Swaim; Sean F Hackett; Lorenza Wyder; Susanne Worpenberg; Samuel Barbieri; Peter A Campochiaro
Journal:  FASEB J       Date:  2008-04-01       Impact factor: 5.191

9.  Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.

Authors:  Scott Kopetz; Donald P Lesslie; Nikolas A Dallas; Serk I Park; Marjorie Johnson; Nila U Parikh; Michael P Kim; James L Abbruzzese; Lee M Ellis; Joya Chandra; Gary E Gallick
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

10.  Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.

Authors:  Lauren Averett Byers; Banibrata Sen; Babita Saigal; Lixia Diao; Jing Wang; Meera Nanjundan; Tina Cascone; Gordon B Mills; John V Heymach; Faye M Johnson
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.